Home / Psoriasis / Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis

Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis

Brief Summary:
Researchers want to find out if giving the drug Apremilast in combination with Clobetasol spray can help people clear their moderate to severe plaque psoriasis quicker than if Apremilast is used by itself.

Condition or disease Intervention/treatment Phase
Psoriasis Combination Product: Apremilast and Clobetasol Phase 4

Detailed Description:
People over age 18 with moderate to severe plaque psoriasis who choose to be in the study and pass the four week screening period will visit the study center about 8 times over about 16 weeks. All participants will be given Apremilast, a pill that you take in the morning and at night, and which studies have shown may reduce inflammation and improve psoriasis symptoms. All participants will also be given Clobetasol to spray twice daily for two weeks, then once daily for two weeks, then every other day for two weeks. All drugs and study visits are at no cost to participants.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment :20 participants
Intervention Model:Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title:Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis
Actual Study Start Date :February 25, 2018
Estimated Primary Completion Date :March 1, 2020
Estimated Study Completion Date :June 30, 2020
Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

U.S. FDA Resources

About

Check Also

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Study Description Go to  Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation. Condition …

Leave a Reply

Your email address will not be published. Required fields are marked *